M&AVectivBio taken over in $1bn acquisitionGI specialist Ironwood Pharmaceuticals Inc. has announced to acquire Swiss VectivBio Holding AG for $17 per share in an all-cash transaction. more ➔
AIAI predicts an enzyme’s substrateA new machine learning model can predict enzyme-substrate pairs, with an accuracy of over 90% and is ready to be used in pharmaceutical and industrial biotechnology. more ➔
decarbonisationLanzaTech and Plastipak produce greener PETCarbon-capture specialist LanzaTech Global and Plastipak Packaging Inc have produced the world’s first PET resin made from captured carbon emissions. more ➔
Multiple sclerosisRoche’s meets endpoints in relapsing multiple sclerosisRoche’s bruton’s tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis. more ➔
CGTuniQure sells royalty interest in gene therapy for $400muniQure N.V. is to sell a portion of its royalty rights from the net sales o its hemophilia B gene therapy etranacogene dezaparvovec-drbl to HealthCare Royalty and Sagard Healthcare for a gross purchase … more ➔
financingDualyx NV raises €40m in Series A financing Belgian T reg specialist Dualyx NV had raised €40m to progress its three preclinical Treg candidates for autoimmune diseases into the clinic. more ➔
RSVSanofi’s/Astazeneca’s anti-RSV antibody highly effectiveNHS research partners of AstraZeneca and Sanofi have reported a 83% reduction in RSV infant hospitalisations in a post-approval clinical trial. more ➔
partnershipMainz Biomed Partners with Microba Life SciencesMolecular diagnostics specialist Mainz Biomed NV has inked a research collaboration with precision microbiome firm Microba Life Sciences Inc. more ➔
financingDiogenX SA raises €27.5M in Series A financing French pancreatic beta-cell modulator specialist DiogenX SA has raised €27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund. more ➔
M&AWacker AG expands biotech business through €100m acquisitionMunich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for €100m. more ➔
